Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22752Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Yang, J C-H | - |
| dc.contributor.author | Ramalingam, S S | - |
| dc.contributor.author | Lee, C K | - |
| dc.contributor.author | Kurata, T | - |
| dc.contributor.author | Kim, D-W | - |
| dc.contributor.author | John, Thomas | - |
| dc.contributor.author | Nogami, N | - |
| dc.contributor.author | Ohe, Y | - |
| dc.contributor.author | Rukazenkov, Y | - |
| dc.contributor.author | Murphy, M | - |
| dc.contributor.author | Jänne, P A | - |
| dc.date.accessioned | 2020-03-10T22:06:20Z | - |
| dc.date.available | 2020-03-10T22:06:20Z | - |
| dc.date.issued | 2019-04 | - |
| dc.identifier.citation | Annals of oncology : official journal of the European Society for Medical Oncology 2019; 30 Suppl 2: ii48 | - |
| dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/22752 | - |
| dc.language.iso | eng | - |
| dc.title | Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts. | - |
| dc.type | Journal Article | - |
| dc.identifier.journaltitle | Annals of oncology : official journal of the European Society for Medical Oncology | - |
| dc.identifier.affiliation | National Taiwan University and National Taiwan University Cancer Center, Taipei City, Taiwan | - |
| dc.identifier.affiliation | Austin Health, Heidelberg, Victoria, Australia | en |
| dc.identifier.affiliation | St. George Hospital, Sydney, Australia | en |
| dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia | en |
| dc.identifier.affiliation | Emory School of Medicine, Winship Cancer Institute, Atlanta, GA, USA | - |
| dc.identifier.affiliation | Kansai Medical University Hospital, Osaka, Japan | - |
| dc.identifier.affiliation | Seoul National University Hospital, Seoul, Republic of Korea | - |
| dc.identifier.affiliation | National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan | - |
| dc.identifier.affiliation | Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan | - |
| dc.identifier.affiliation | AstraZeneca, Cambridge, UK | - |
| dc.identifier.affiliation | Dana-Farber Cancer Institute, Boston, MA, USA | - |
| dc.identifier.doi | 10.1093/annonc/mdz063.020 | - |
| dc.identifier.pubmedid | 32131238 | - |
| dc.type.austin | Journal Article | - |
| local.name.researcher | John, Thomas | |
| item.fulltext | No Fulltext | - |
| item.openairetype | Journal Article | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| item.grantfulltext | none | - |
| item.languageiso639-1 | en | - |
| item.cerifentitytype | Publications | - |
| crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
| crisitem.author.dept | Medical Oncology | - |
| crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
| Appears in Collections: | Journal articles | |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.